Phase 4 Vasculitis Trial, Recruiting NCT05962840 Sponsor: Chinese SLE Treatment And Research Group Condition: Vasculitis
Back to Vasculitis

Phase 4 Vasculitis Trial, Recruiting

NCT05962840
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 65 years old (any gender)
  • You have been newly diagnosed with, or are experiencing a return of, a condition called granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), confirmed using recognized medical classification standards
  • Your condition is currently considered severely active, based on a specific medical definition from 2021
  • A particular antibody called PR3-ANCA has been found in your blood, either at the time of diagnosis or at some point during your illness

Who may not be able to join:

  • You previously tried a medication called Rituximab but had to stop because of side effects or because your body did not tolerate it
  • You have another autoimmune disease in addition to the one being studied
  • You have serious liver problems, heart failure, or very poor kidney function (confirm with trial site for exact definitions)
  • You are pregnant or planning to become pregnant within the next 2 years
  • You have high blood pressure, diabetes, or an active bacterial or fungal infection that is not well controlled
  • You have an active hepatitis virus infection or an active tuberculosis-related (mycobacteria) infection
  • You have or have had cancer
  • The trial doctors determine for any other reason that participation would not be appropriate for you (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Jing Li, MD, Peking Unione Mdecial College Hospital

Phone: 86-13671313079

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Chinese SLE Treatment And Research Group
Registry
ClinicalTrials.gov
Start date
29 June 2023
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The time of first relapse during 24 months follow-up of two groups

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov